Spectrum Brands Slips To Loss In Q4

Consumer products company Spectrum Brands Holdings, Inc. (SPB) reported Friday a net loss from continuing operations of $24.8 million or $0.61 per share, compared to net income of $6.1 million or $0.14 per share in the prior-year quarter.

Excluding items, adjusted earnings from continuing operations was $0.48 per share, compared to $0.38 per share in the year-ago quarter.

Net sales decreased 1.1 percent to $749.5 million from $757.8 million in the same quarter last year, with significant unfavorable foreign currency impact. Net sales grew 7.3 percent organically, excluding the impact of fx and acquisition.

"Our latest financial results for the fourth quarter complete a challenging year for our business where we faced high input cost inflation, supply chain disruptions, and cost headwinds related to currency changes," said David Maura, Chairman and CEO.

Looking ahead to fiscal 2023, the company now expects to deliver low single-digit net sales growth, with foreign exchange expected to have a negative impact based upon current rates.

The company also said it expects to collect $4.3 billion upon completion of the sale of HHI, which is anticipated to close no later than the end of June 2023.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT